Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.70 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.70 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.58 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | FAP | Q12884 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7919249 | 0.89 | DPP4 (0.58) | DPP4DPP9DPP8DPP7ACE | |
| SCHEMBL5935877 | 0.88 | DPP4 (0.72) | DPP4DPP9DPP8DPP7ACE | |
| SCHEMBL5935836 | 0.88 | DPP4 (0.72) | DPP4DPP9DPP8DPP7ACE | |
| SCHEMBL1509255 | 0.85 | DPP4 (0.72) | DPP4DPP9DPP8DPP7ACE | |
| SCHEMBL15344691 | 0.85 | DPP4 (0.57) | DPP4DPP9DPP8DPP7ACE | |
| SCHEMBL29361968 | 0.85 | DPP4 (0.72) | DPP4DPP9DPP8DPP7ACE | |
| SCHEMBL3715380 | 0.85 | DPP4 (0.72) | DPP4DPP9DPP8DPP7ACE | |
| SCHEMBL30535978 | 0.85 | DPP4 (0.72) | DPP4DPP9DPP8DPP7ACE | |
| SCHEMBL5935838 | 0.85 | DPP4 (0.57) | DPP4DPP9DPP8DPP7ACE | |
| SCHEMBL5417652 | 0.85 | DPP4 (0.51) | DPP4DPP9DPP8DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583534-A4 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20060052382-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. | 2006-03-09 | — | — | US | disclosed |
| EP-1583534-A1 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004058266-A1 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052382-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885DPP9 4/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.